Menu Menu

Caring for people with Monkeypox (MPX)

Supporting Australia’s healthcare professionals with continually updated, evidence-based clinical guidelines

27/03/23: Communique from the National Steering Committee


Evidence-based clinical Monkeypox (MPX) guidelines updated with the latest research

under review

Continuously reviewing new evidence to update recommendations and address new priority questions

We are currently reviewing evidence to develop recommendations to guide practice in areas including:

  • No current evidence under review

Expert Panels

Do you have a clinical question?

Your views help us to identify and prioritise questions to include in the living guideline.

envelope iconSubscribe here to receive regular updates from the Taskforce


Please enter your email, so we can follow up with you.


Suggest a new topic or clinical question. Please note that our living guideline aims to

“Provide specific, patient-focused recommendations for the clinical care of people with suspected or confirmed COVID-19, where care for this patient group differs from usual care provided to patients with similar clinical conditions (pneumonia, severe acute respiratory distress, etc.)”.

*The following topics for COVID-19 are currently included:

• Definition of disease severity
• Monitoring and markers of clinical deterioration
• Drug treatments (e.g. antimalarials)
• Chemoprophylaxis
• Respiratory support in adults
• Respiratory support in neonates, children and adolescents
• Venous thromboembolism (VTE) prophylaxis
• Therapies for existing indications in patients with COVID-19
• Care of people after COVID-19
• Timing of surgery following COVID-19 infection
• Pregnancy and perinatal care
• Child and adolescent care

*The following topics for MPX are currently included:

• Disease severity and risk of severe disease
• Drug treatments
• Supportive care
• Pregnancy and perinatal care
• Paediatric and adolescent care


Please enter your email to receive our regular updates.

and funders